Neuroimmunomodulatory effects of transcranial laser therapy combined with intravenous tPA administration for acute cerebral ischemic injury
At present, the only FDA approved treatment for ischemic strokes is intravenous administration of tissue plasminogen activator within 4.5 hours of stroke onset. Owing to this brief window only a small percentage of patients receive tissue plasminogen activator. Transcranial laser therapy has been sh...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications & Media Pvt Ltd
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590216/ |